Fetale Wachstumsrestriktion: Prädiktion mittels Doppler-Sonografie und angiogene Faktoren zur Vorhersage

Sven Kehl

doi:10.1055/s-0043-115422

Geburtshilfe und Frauenheilkunde, Table of Contents

Geburtshilfe Frauenheilkd 2017; 77(09): 957-959
DOI: 10.1055/s-0043-115422

GebFra Magazin

Aktuell diskutiert

Georg Thieme Verlag KG Stuttgart · New York

Fetale Wachstumsrestriktion: Prädiktion mittels Doppler-Sonografie und angiogene Faktoren zur Vorhersage

Sven Kehl

Abstract

Full Text

References

Literatur
1 Albu AR, Anca AF, Horhoianu VV. et al. Predictive factors for intrauterine growth restriction. J Med Life 2014; 7: 165-171
2 Parker SE, Werler MM. Epidemiology of ischemic placental disease: a focus on preterm gestations. Semin Perinatol 2014; 38: 133-138
3 McIntire DD, Bloom SL, Casey BM. et al. Birth weight in relation to morbidity and mortality among newborn infants. N Engl J Med 1999; 340: 1234-1238
4 Alkalay AL, Graham jr. JM, Pomerance JJ. Evaluation of neonates born with intrauterine growth retardation: review and practice guidelines. J Perinatol 1998; 18: 142-151
5 Pallotto EK, Kilbride HW. Perinatal outcome and later implications of intrauterine growth restriction. Clin Obstet Gynecol 2006; 49: 257-269
6 Barker DJ. Adult consequences of fetal growth restriction. Clin Obstet Gynecol 2006; 49: 270-283
7 Froen JF, Gardosi JO, Thurmann A. et al. Restricted fetal growth in sudden intrauterine unexplained death. Acta Obstet Gynecol Scand 2004; 83: 801-807
8 Richardus JH, Graafmans WC, Verloove-Vanhorick SP. et al. Differences in perinatal mortality and suboptimal care between 10 European regions: results of an international audit. BJOG 2003; 110: 97-105
9 Akolekar R, Syngelaki A, Sarquis R. et al. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks. Prenat Diagn 2011; 31: 66-74
10 Karagiannis G, Akolekar R, Sarquis R. et al. Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11–13 weeks. Fetal Diagn Ther 2011; 29: 148-154
11 Beaufils M, Uzan S, Donsimoni R. et al. Prevention of pre-eclampsia by early antiplatelet therapy. Lancet 1985; 1: 840-842
12 Bujold E, Roberge S, Lacasse Y. et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010; 116: 402-414
13 Henderson JT, Whitlock EP, OʼConnor E. et al. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2014; 160: 695-703
14 Askie LM, Duley L, Henderson-Smart DJ. et al. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 369: 1791-1798
15 Roberge S, Nicolaides KH, Demers S. et al. Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. Ultrasound Obstet Gynecol 2013; 41: 491-499
16 Caron N, Rivard GE, Michon N. et al. Low-dose ASA response using the PFA-100 in women with high-risk pregnancy. J Obstet Gynaecol Can 2009; 31: 1022-1027
17 Rey E, Rivard GE. Is testing for aspirin response worthwhile in high-risk pregnancy?. Eur J Obstet Gynecol Reprod Biol 2011; 157: 38-42
18 Ayala DE, Ucieda R, Hermida RC. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. Chronobiol Int 2013; 30: 260-279
19 Norgard B, Puho E, Czeizel AE. et al. Aspirin use during early pregnancy and the risk of congenital abnormalities: a population-based case-control study. Am J Obstet Gynecol 2005; 192: 922-923
20 Werler MM, Mitchell AA, Shapiro S. The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. N Engl J Med 1989; 321: 1639-1642
21 Rotchell YE, Cruickshank JK, Gay MP. et al. Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. Br J Obstet Gynaecol 1998; 105: 286-292
22 Caritis S, Sibai B, Hauth J. et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1998; 338: 701-705
23 Sibai BM, Caritis SN, Thom E. et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1993; 329: 1213-1218
24 Duley L, Henderson-Smart DJ, Meher S. et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007; (02) CD004659
25 Schiessl B, Schneider KT, Zimmermann A. et al. Prenatal constriction of the fetal ductus arteriosus–related to maternal pain medication?. Z Geburtshilfe Neonatol 2005; 209: 65-68
26 Wyatt-Ashmead J. Antenatal closure of the ductus arteriosus and hydrops fetalis. Pediatr Dev Pathol 2011; 14: 469-474
27 Intrauterine growth restriction. Guideline of the German Society of Gynecology and Obstetrics (S2k, AWMF-Registry-No.: 015/080, October 2016). Online: http://www.awmf.org/leitlinien/detail/ll/015-080.html Stand: 01.07.2017
28 Rolnik DL, Wright D, Poon LC. et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017;